NCT00540670

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Eisai Co., Ltd. · Industry
• Sex: All
• Age: 45 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	E5555 50 mg	E5555 50 mg (tablet) taken orally, once a day.
DRUG	E5555 100 mg	E5555 100 mg (tablet) taken orally, once a day.
DRUG	E5555 200 mg	E5555 200 mg (tablet) taken orally, once a day.
DRUG	Placebo	Placebo (tablet) taken orally, once a day.

Timeline

• Start date: 2007-10-01
• Primary completion: 2009-03-01
• First posted: 2007-10-08
• Last updated: 2013-05-13

Locations

25 sites across 1 country: Japan